Streetbeat News

Price Targets

ABSI

Absci (NASDAQ:ABSI) has received mixed analyst ratings over the past three months, with 4 analysts offering diverse views ranging from bullish to bearish. The average 12-month price target is $4.75, up from the previous $3.50, with a high estimate of $7.00 and a low of $3.00. Analysts from HC Wainwright & Co. and Keybanc have raised their price targets, reflecting a positive outlook on the company's performance. Despite a significant market capitalization, Absci faces revenue challenges with a -68.59% decline over 3 months. However, the company has a high net margin of -2956.18%, an ROE of -10.68%, and an ROA of -8.97%, with a low debt-to-equity ratio of 0.09.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 7:01 pm

IRTC

iRhythm Technologies (NASDAQ:IRTC) has been analyzed by 6 analysts, showing a range of opinions from bullish to bearish. The average 12-month price target is $122.83, with a high of $136.00 and a low of $108.00, indicating a slight increase from the previous average of $122.40. Analysts from firms including Needham, Truist Securities, Citigroup, and Morgan Stanley have updated their ratings and price targets, reflecting their views on the company's performance and market conditions. iRhythm Technologies, a digital healthcare company, has seen a revenue growth of 19.96% as of September 30, 2023, but faces challenges with below-average net margin, ROE, and ROA, despite a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 7:01 pm

VTLE

Analysts have mixed views on Vital Energy (NYSE:VTLE), with recent ratings ranging from bullish to bearish. Over the last quarter, the total ratings included 4 bullish, 2 somewhat bullish, 1 indifferent, and 1 somewhat bearish. The average 12-month price target is now $62.75, down from $76.75, indicating an 18.24% decrease. Analysts from firms like Raymond James, Truist Securities, and others have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Vital Energy, an independent energy company operating in the Permian Basin, has seen a -6.16% decline in revenue growth and has financial metrics below industry averages, including a net margin of 1.12% and an ROE of 0.29%.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 7:00 pm

PCAR

PACCAR (NASDAQ:PCAR) received mixed analyst ratings in the latest quarter, with 1 bullish, 3 somewhat bullish, and 1 indifferent rating. The 12-month price targets have an average of $108.8, with a high of $125 and a low of $92, marking a 12.75% increase from the previous average target of $96.50. Analysts from Morgan Stanley, JP Morgan, Citigroup, and Deutsche Bank have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. PACCAR, known for its Kenworth, Peterbilt, and DAF trucks, has a strong market position with significant revenue growth, high net margin, and excellent ROE and ROA, along with a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 7:00 pm

CB

MET

VOYA

Goldman Sachs analyst Alex Scott has updated ratings on several insurance stocks, with a positive outlook for life insurers in 2024. MetLife Inc (MET) was upgraded to Buy with a price target of $80, citing strong growth and capital position. Voya Financial Inc (VOYA) was downgraded to Neutral with a price target of $82, due to competitive market challenges and earnings volatility. Chubb Ltd (CB) was also downgraded to Neutral with a price target of $222, facing pricing deceleration and reserve release challenges. MET's stock is trading slightly higher, while VOYA and CB are trading lower.

Portfolio Pulse from Lekha Gupta

January 08, 2024 | 6:43 pm

HARP

HC Wainwright & Co. analyst Swayampakula Ramakanth downgraded Harpoon Therapeutics (NASDAQ:HARP) from Buy to Neutral, while increasing the price target from $12 to $23.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 6:41 pm

AMAM

DTC

HARP

LMDX

RXST

RxSight, Inc. (RXST) shares surged by 20% after providing FY23 and FY24 revenue guidance above estimates and following a price target increase by Needham. Other stocks experienced significant movement, with Harpoon Therapeutics, Inc. (HARP) and Ambrx Biopharma Inc. (AMAM) seeing major gains due to acquisition announcements. Conversely, LumiraDx Limited (LMDX) and Solo Brands, Inc. (DTC) faced steep declines, with LumiraDx facing Nasdaq suspension and Solo Brands lowering its full year 2023 revenue guidance.

Portfolio Pulse from Avi Kapoor

January 08, 2024 | 6:36 pm

IRTC

Needham analyst David Saxon has reaffirmed a Buy rating on iRhythm Technologies (NASDAQ:IRTC) and increased the price target from $108 to $136, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 6:33 pm

CBOE

Rosenblatt analyst Andrew Bond has reiterated a Buy rating on Cboe Global Markets (CBOE) and maintained a $192 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 6:17 pm

SEIC

Oppenheimer analyst Owen Lau has reaffirmed an Outperform rating on SEI Investments Company (NASDAQ:SEIC) and increased the price target from $65 to $71, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 6:15 pm